Compare Abeona Therapeutics Inc (ABEO) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Abeona Therapeutics Inc trades at $6.36 (market cap $425.47M), while Consumer Discretionary Select Sector SPDR Fund trades at $118.5. Which is the better fit depends on your goals.
| ABEO | XLY | |
|---|---|---|
Market Cap | $425.47M | — |
Sector | Health | — |
52-Week High | $7.46 | $124.52 |
52-Week Low | $4.17 | $105.64 |
Enterprise Value | $280.37M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.81% today, with a bullish technical outlook supported by moving averages but overbought RSI signals. The company reported Q2 2026 revenue of $11.4 million, missing EPS estimates, yet maintains strong profitability margins and low valuations. Recent news highlights operational challenges with ZEVASKYN rollout but positive developments like CMS NTAP status.
Outlook is mixed: analyst consensus is bullish with 67% buy ratings, but risks include execution setbacks and shareholder investigations. Investment opportunity lies in growth potential if operational issues resolve, though high volatility and negative cash flows from operations pose near-term headwinds.
XLY trades at $117.89, down 1.13% on the day, with a bullish technical signal driven by moving averages. Analyst consensus is unanimously positive, with a 100% buy rating. Recent news highlights consumer discretionary as a potential dark horse, with spending shifting toward value and convenience. The ETF offers exposure to resilient consumer trends, though inflation and sentiment remain headwinds.
The outlook for XLY is supported by strong technical momentum and optimistic analyst coverage, but risks include inflation pressures and weak consumer confidence. Upside depends on sustained discretionary spending and broader economic stability. Investors should weigh the ETF's liquidity and sector positioning against macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
